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Background: Proctitis after radiation therapy for prostate cancer remains an ongoing clinical challenge and critical
quality of life issue. SBRT could minimize rectal toxicity by reducing the volume of rectum receiving high radiation
doses and offers the potential radiobiologic benefits of hypofractionation. This study sought to evaluate the
incidence and severity of proctitis following SBRT for prostate cancer.
Methods: Between February 2008 and July 2011, 269 men with clinically localized prostate cancer were treated
definitively with SBRT monotherapy at Georgetown University Hospital. All patients were treated to 35-36.25Gy in 5
fractions delivered with the CyberKnife Radiosurgical System (Accuray). Rectal bleeding was recorded and scored
using the CTCAE v.4. Telangiectasias were graded using the Vienna Rectoscopy Score (VRS). Proctitis was assessed
via the Bowel domain of the Expanded Prostate Index Composite (EPIC)-26 at baseline and at 1, 3, 6, 9, 12, 18 and
24 months post-SBRT.
Results: The median age was 69 years with a median prostate volume of 39 cc. The median follow-up was 3.9 years
with a minimum follow-up of two years. The 2-year actuarial incidence of late rectal bleeding ≥ grade 2 was 1.5%.
Endoscopy revealed VRS Grade 2 rectal telangiectasias in 11% of patients. All proctitis symptoms increased at
one month post-SBRT but returned to near-baseline with longer follow-up. The most bothersome symptoms
were bowel urgency and frequency. At one month post-SBRT, 11.2% and 8.5% of patients reported a moderate
to big problem with bowel urgency and frequency, respectively. The EPIC bowel summary scores declined transiently
at 1 month and experienced a second, more protracted decline between 6 months and 18 months before returning
to near-baseline at two years post-SBRT. Prior to treatment, 4.1% of men felt their bowel function was a moderate
to big problem which increased to 11.5% one month post-SBRT but returned to near-baseline at two years
post-SBRT.
Conclusions: In this single institution cohort, the rate and severity of proctitis observed following SBRT is
low. QOL decreased on follow-up; however, our results compare favorably to those reported for patients
treated with alternative radiation modalities. Future prospective randomized studies are needed to confirm
these observations.
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Post-treatment bowel function is a primary determinant
of quality of life following radiation therapy for prostate
cancer [1-5]. Late proctitis occurs at a frequency of 5–
20% with conventionally fractionated treatment [6]. The
incidence of proctitis is dependent on the assessment
method [7] and whether it is patient or physician re-
ported [8]. Patients with radiation-induced proctitis re-
port increased bowel frequency/urgency, incontinence,
bleeding and pain [6]. These symptoms occur months to
years after treatment with the large majority of patients
reporting symptoms within two years following radiation
therapy [9]. Patient characteristics such as age [10], co-
morbidities [10], hemorrhoids, inflammatory bowel dis-
ease [11] and/or anticoagulation [12] may increase an
individual’s risk of radiation-induced proctitis. Unfortu-
nately, treatment options for radiation proctitis are lim-
ited and of unclear clinical benefit [13].
Proctitis is the principle dose-limiting toxicity of pros-
tate radiotherapy [14-16]. Acute proctitis has been at-
tributed to radiation-induced injury to the epithelial
lining of the rectal mucosa, leading to mucosal sloughing,
acute inflammatory infiltrates, and vascular permeability
leading to edema. These early changes are associated
with bowel frequency, bowel urgency and rectal pain.
Chronic proctitis results from epithelial atrophy and ob-
literative endarteritis, resulting in tissue ischemia, rectal
fibrosis, stricture formation, and neovascularization; this
presents clinically with bowel frequency, urgency and
rectal bleeding. Historically, endoscopic findings in pa-
tients with proctitis include telangiectasia, congested mu-
cosa, and ulcers. Telangiectasias are observed in 20-80%
of patients receiving conventionally fractionated radiation
therapy [17].
The risk of proctitis appears to be dependent upon
both the total radiation dose and the volume of the rec-
tum in the high dose area [18]. Technical factors such as
treatment of the proximal seminal vesicles [19] and ex-
pansion of planning target volume (PTV) to compensate
for intra-fraction prostate motion [20] may contribute to
the severity of rectal toxicities. To minimize bowel tox-
icity, it is currently recommended that the volume of the
rectum receiving > 75 Gray (Gy) be limited to < 10% with
conventionally fractionated radiation therapy [21,22].
Studies have shown that advanced radiation technologies
such as intensity modulated radiation therapy (IMRT)
may decrease the dose to the rectum and potentially de-
crease proctitis [23,24].
Recent data suggest that large radiation fraction sizes
are radiobiologically favorable over lower fraction sizes
in prostate cancer [25]. The α/β for prostate cancer may
be as low as 1.5 Gy [26]. If the α/β for prostate cancer is
less than 3-5 Gy, which is generally the value accepted
for late rectal complications, the linear-quadratic modelpredicts that delivering large radiation fraction sizes will
result in improved local control with a similar rate of
bowel complications. Therefore, using large fraction sizes
in SBRT provides an attractive modality to leverage the
potential radiobiologic benefits of hypofractionation with
the minimal invasiveness of an external-beam treatment
modality [27]. Furthermore, by reducing the number of
treatment visits, hypofractionated therapy can also be
logistically favorable for patients and reduce financial
burden, ultimately decreasing barriers to care.
The safety and efficacy of SBRT in the treatment of
clinically localized prostate cancer has been established
in a number of studies [28-33]. The use of large fraction
sizes in SBRT offers the potential radiobiological benefits
of hypofractionation and potentially may minimize radi-
ation proctitis by reducing the volume of the rectum
receiving high radiation doses [34]. The CyberKnife ro-
botic radiosurgical system uses image guidance to track
implanted fiducials to account for intrafraction prostatic
motion [35,36]. This reduces the uncertainty of the loca-
tion of the prostate and allows treatment to be delivered
with a smaller PTV expansion, which may reduce the
doses delivered to the anterior rectal wall. The goal of
this study is to report the bowel outcomes following
SBRT for clinically localized prostate cancer.
Methods
Patient selection
Patients eligible for study inclusion had histologically-
confirmed prostate cancer treated per our institutional
protocol. Clinical stage was defined according to the 6th
edition of the American Joint Committee on Cancer
criteria. Risk groups were defined using the D’Amico
criteria [37]. Internal Review Board (IRB)-approval was
obtained for retrospective review of data that was pro-
spectively collected in our institutional database.
SBRT treatment planning and delivery
SBRT was delivered using the CyberKnife robotic radio-
surgical system (Accuray Inc., Sunnyvale, CA). The fidu-
cial placement and computed tomography (CT)/magnetic
resonance (MR) simulation procedures have been previ-
ously described in Lei et al. [36]. The clinical target
volume (CTV) was defined as the prostatic capsule and
proximal seminal vesicles (to the point where the seminal
vesicles separate). To cover areas of potential ECE, the ex-
pansion from the CTV to the PTV was 5 mm in all direc-
tions except 3 mm posteriorly into the rectum. There was
no difference in the target volume delineation for different
risk groups. Fiducial-based tracking was used to account
for interfraction and intrafraction prostate motion [35].
Treatment planning was performed using Multiplan
(Accuray Inc., Sunnyvale, CA). Patients were treated with
35 or 36.25 Gy of radiotherapy delivered in 5 fractions of
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of 1-2 weeks. This corresponds to a tumor equivalent
dose in 2-Gy fractions (EQD2) of approximately 85-
90 Gy assuming an α/β ratio of 1.5. The rectum was con-
toured as a solid structure from the anus (at the level of
the ischial tuberosities) to the rectosigmoid flexure
and evaluated with dose-volume histogram analysis
during treatment planning using Multiplan (Accuray Inc.,
Sunnyvale, CA) inverse treatment planning. Rectal volume
receiving 36 Gy was limited to ≤ 1 cc. Assuming an α/β of
3 Gy for late bowel complications, this is biologically
equivalent to approximately 74 Gy administered in 2 Gy
fractions. The rectal dose-volume histogram (DVH) goals
were <50% rectal volume receiving 50% of the prescribed
dose, <20% receiving 80% of the dose, <10% receiving
90% of the dose, and < 5% receiving 100% of the dose.
Typical dose distributions have been previously described
[28,34,38]. Patients were placed on a low-residual diet and
given enemas prior to simulation and treatment delivery
to maximize the potential distance between the prostate
and the rectal wall and minimize intrafraction prostate
motion.
Follow-up and statistical analysis
Rectal bleeding was prospectively documented at follow-
up visits using the National Cancer Institute (NCI)
Common Toxicity Criteria (CTC) version 4.0. Acute rec-
tal bleeding was defined as experiencing toxicity within
6 months of radiation therapy. Late rectal bleeding
was defined as occurring at least 6 months after de-
livery of radiation therapy. Grade 1 represents minimal
bleeding not requiring medications for symptom control.
Grade 2 indicates rectal bleeding requiring new medica-
tion (i.e. steroid suppository) or minor laser coagulation.
Telangiectasia were graded using the Vienna Rectoscopy
Score (VRS): Grade 1 (a single telangiectasia), Grade 2
(multiple non-confluent telangiectasia) and Grade 3 (mul-
tiple confluent telangiectasia) [39].
Proctitis was assessed via the bowel domain of the
Expanded Prostate Index Composite (EPIC)-26 at base-
line and at 1, 3, 6, 9, 12, 18 and 24 months [40]. The
timing of the quality of life (QOL) assessments was rela-
tive to the last day of SBRT treatment. The EPIC-26
bowel domain includes five questions related to individ-
ual symptoms (questions 6a-e: urgency, frequency, pain,
bloody stool, incontinence) and one question (question 7)
related to overall bother (degree of interference or annoy-
ance caused by bowel symptoms [41].
Wilcoxon signed-rank test and chi-square analysis were
used to assess differences in ongoing quality of life scores
in comparison to baseline. For each EPIC question, the re-
sponses were grouped into three clinically relevant categor-
ies (no problem, very small-small problem and moderate
to big problem). To statistically compare changes betweentime points, the levels of responses were assigned a score
and the significance of the mean changes in the scores was
assessed by Wilcoxon rank test. EPIC scores for the bowel
domain and its individual questions range from 0 - 100
with lower values representing worsening bowel symp-
toms. The minimally important difference (MID) in EPIC
score was defined as a change of one-half standard devi-
ation (SD) from the baseline [42]. To limit the effect of at-
trition bias, statistical analysis was limited to time points in
which ≥ 80% of the patient data were available.
Results
From February 2008 to July 2011, 269 prostate cancer
patients were treated per our institutional SBRT mono-
therapy protocol (Table 1). The median follow-up was
3.9 years. The median age was 69 years and 44.2% were
of non-Caucasian ancestry. Comorbidities were common
with 35% were taking anticoagulants (including aspirin)
prior to treatment. The median prostate volume was
39 cc. By D’Amico classification, 99 patients were low-,
143 intermediate-, and 27 high-risk. 16.4% also received
androgen deprivation therapy (ADT) at the discretion of
the treating Urologist. 83.3% of the patients were treated
with 36.25 Gy in five 7.25 Gy fractions.
A total of 61 (22.7%) patients reported rectal bleeding
after SBRT, with 28 (10.4%) patients reporting acute
bleeding and 38 patients (14.1%) reporting late bleeding.
Overall, Grade 2 acute and late rectal bleeding were ob-
served in 0 (0%) and 4 (1.5%) of patients, respectively.
There was no Grade 3 or higher rectal bleeds. The ma-
jority of acute rectal bleeding occurred within 1-month
post-SBRT treatment (79%). The bleeding completely re-
solved in the majority of the patients by the subsequent
follow-up visit. Likewise, the majority of late rectal
bleeding was observed at one specific follow-up appoint-
ment and did not persist on subsequent follow-ups.
Seventy-three patients had one or more rectal endos-
copies during the follow-up period. Endoscopy was per-
formed as a part of normal colorectal cancer screening
or if patient had clinically significant rectal bleeding.
The median interval from completion of SBRT to endos-
copy was 24 months (3 months to 53 months). On en-
doscopy, rectal telangiectasias were found in 8 (11.0%)
patients. All 8 patients were observed to have multiple
non-confluent telangiectasias (VRS Grade 2) [38]. No
patient had confluent or circumferential telangiectasia.
Minor laser coagulation was performed in three pa-
tients. No rectal ulcerations, strictures, or fistulas were
observed.
At baseline, 1.9% of our cohort reported some level of
annoyance due to bloody stools, however no patient felt
it was a moderate to big problem (Table 2). The mean
changes in EPIC bloody stool bother scores from base-
line to 2 years of follow-up are shown in Table 3. The
Table 1 Baseline patient characteristics and treatment
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(Table 3). Bloody stool bother increased following treat-
ment with the mean score decreasing to 96.6 at 1 month
post-treatment (mean change, -2.9) (p = 0.0002) (Table 3,
Figure 1d). However, only 1.2% of patients felt that that
bloody stools were a moderate to big problem at 1 month
following treatment (Table 2). Although bloody stool
bother declined quickly, a second late increase in
bloody stool bother was observed with the mean bloodystool bother score decreasing to 97.4 at 18 months
(mean change from baseline, -2.1) (p = 0.0066) (Table 3,
Figure 1d). Both declines met the threshold for clinic-
ally significant change (MID = 1.7). However, only 1.2%
of patients felt that that bloody stools were a moder-
ate to big problem at 12 months following treatment
(Table 2). By two years following SBRT, bloody stool
bother returned to near-baseline with bloody stool bother
score of 98.1 (mean change from baseline, -1.4). By two
years post-SBRT, no patient felt that blood stools was a
moderate to big problem (Table 2).
Baseline proctitis symptoms were uncommon in our
patients (Table 2). All proctitis symptoms increased at
one month post-SBRT. The most bothersome symp-
toms were bowel urgency and frequency. At one
month post SBRT, 11.2% and 8.5% of patients reported
moderate to big problems with bowel urgency and
frequency, respectively (Table 2). 9.7% of patients re-
quired anti-diarrheals within the first month post-
SBRT.
Likewise, the EPIC bowel summary score declined
transiently at 1 month (mean change, -9.8) (Table 3). In
addition, a second more protracted decline occurred be-
tween 6 and 18 months (mean change from baseline
at 12 months, -3.5). Bowel declines at 1 month and
12 months were statistically significant (p < 0.0001);
however, only the 1 month change met the threshold for
clinically significant change (MID = 4.6) (Figure 2). The
EPIC bowel summary score returned to near-baseline at
two years post-SBRT (mean change from baseline, -1.6).
Individual bowel symptoms changed with time in a simi-
lar manner (Figure 1).
Overall bowel bother showed a similar pattern as
the bowel summary score. At baseline, 24.0% of pa-
tients reported some level of annoyance due to bowel
symptoms with 4.1% of patients feeling that bowel
function was a moderate to big problem (Table 4).
The mean EPIC bowel bother score was 90.7 at base-
line (Table 3). Overall bowel bother worsened post-
treatment and the mean score decreased to 75 at
1 month (mean change, -14.8) (Table 3, Figure 3). How-
ever, only 11.5% of patients felt that their bowel function
was a moderate to big problem at 1 month following
SBRT (Table 4). Bowel bother scores worsened over a
second, more protracted time period (Figure 3). Once
again, only the first decline met the threshold for clinic-
ally significant change (MID = 9.8). Only 7% of patients
felt that bowel symptoms were a moderate to big prob-
lem at 12 month following treatment (Table 4). By two
years following SBRT, overall bowel bother returned to
near baseline with a bowel bother score of 89.8 (mean
change from baseline, -0.9) (Table 3) and 3.3% of patients
feeling bowel symptoms were a moderate to big problem
(Table 4).
Table 2 Bowel symptoms following SBRT for prostate cancer
Start 1 3 6 9 12 18 24
Bowel urgency
No problem 77.2% 49.8% 62.0% 60.2% 64.5% 62.3% 64.7% 66.8%
Very small-small problem 21.0% 39.0% 33.7% 34.1% 29.8% 31.6% 29.5% 31.1%
Moderate-big problem 1.9% 11.2% 4.3% 5.6% 5.6% 6.1% 5.8% 2.1%
p value <0.0001 0.0002 <0.0001 0.0002 0.0001 0.0004 0.01568
Bowel frequency
No problem 82.0% 57.0% 71.9% 71.5% 70.6% 72.5% 76.3% 77.4%
Very small-small problem 15.7% 34.5% 25.0% 25.3% 23.4% 23.0% 18.8% 19.7%
Moderate-big problem 2.2% 8.5% 3.1% 3.2% 6.0% 4.5% 4.9% 2.9%
p value <0.0001 0.0079 0.0038 0.0031 0.0214 0.0169 0.2508
Incontinence
No problem 94.8% 79.5% 85.2% 86.7% 88.3% 85.2% 85.7% 89.5%
Very small-small problem 4.1% 17.0% 14.5% 11.2% 9.7% 12.3% 11.6% 8.8%
Moderate-big problem 1.1% 3.5% 0.4% 2.0% 2.0% 2.5% 2.7% 1.7%
p value <0.0001 0.0033 0.0021 0.03 0.0001 0.0001 0.0147
Bloody stools
No problem 98.1% 90.8% 96.9% 95.6% 96.0% 96.3% 94.2% 94.2%
Very small-small problem 1.9% 8.1% 2.3% 3.6% 2.4% 2.5% 5.4% 5.8%
Moderate-big problem 0.0% 1.2% 0.8% 0.8% 1.6% 1.2% 0.4% 0.0%
p value 0.0002 0.1677 0.0934 0.0574 0.0906 0.0066 0.0258
Pain (abdominal, pelvic or rectal)
No problem 86.1% 76.8% 89.8% 86.7% 86.7% 88.5% 86.6% 90.3%
Very small-small problem 12.4% 17.8% 7.8% 10.4% 9.7% 8.2% 12.1% 7.1%
Moderate-big problem 1.5% 5.4% 2.3% 2.8% 3.6% 3.3% 1.3% 2.5%
p value 0.0002 0.5516 0.6606 0.232 0.5713 0.8565 0.7498
N= 267 259 255 249 248 244 224 238
Patient-reported responses to EPIC-26 questions 6A (Urgency to have a bowel movement), 6B (Frequency of bowel movements), 6C (Losing control of your stools),
6D (Bloody stools) and 6E (Abdominal, pelvic or rectal pain).
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Proctitis following prostate cancer radiotherapy is a crit-
ical quality of life issue [1-4] and the principle dose-
limiting toxicity [14-16]. Currently, there is limited data
on proctitis following SBRT for prostate cancer. A better
understanding of bowel symptoms following SBRT would
enable clinicians to provide more realistic expectations
to patients as they weigh their treatment options. Our
prior paper reported the prevalence, severity and overallTable 3 Changes in EPIC bowel summary and overall bowel b
EPIC criteria Baseline 1 Month 6 Month
Change S.D. Change S
Bloody stool bother 99.5 −2.9 12.26 −1.1 8
Bowel summary 94.8 −9.8 17.89 −3.2 1
Bowel bother 90.7 −14.8 26.98 −2.6 2incidence of bowel frequency/urgency, rectal pain and
rectal bleeding following SBRT [28]. However, it is reliant
on physician reporting which may under report the inci-
dence of bowel symptoms [8] and provides no informa-
tion on the associated bother [43,44]. In this study, we
utilized the EPIC-26 bowel domain to evaluate bowel
symptoms but also assess related bother.
Stereotactic body radiation therapy (SBRT) offers to
minimize radiation-associated rectal toxicity by reducingother scores following SBRT for prostate cancer
12 Month 18 Month 24 Month
.D. Change S.D. Change S.D. Change S.D.
.54 −1.3 9.86 −2.1 10.93 −1.4 8.03
2.21 −3.5 13.04 −3.3 13.40 −1.6 10.73
0.82 −5.5 23.95 −3.5 20.91 −0.9 18.86
Figure 1 Individual EPIC-26 bowel symptoms (Questions 6a-e). Average individual symptom EPIC bother scores at baseline and following SBRT
for prostate cancer: (a) urgency to have a bowel movement-Question 6a of the EPIC-26; (b) increase frequency of bowel movements- Question 6b of
the EPIC-26; (c) losing control of stools- Question 6c of the EPIC-26; (d) bloody stools- Question 6d of the EPIC-26; (e) abdominal/pelvic/rectal
pain- Question 6e of the EPIC-26. Thresholds for clinically significant changes in scores (½ standard deviation above and below the baseline) are
marked with dashed lines. EPIC scores range from 0–100 with higher values representing a more favorable health-related QOL.
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The overall incidence of post-SBRT rectal bleeding in
this series was 23%. The low rate of late Grade ≥ 2 rectal
bleeding (1.5%) seen in this study is consistent with the
results from a prior review by our institution [28] and
results from other institutions [45,32] which all report a
rate of late Grade ≥ 2 rectal bleeding of < 5%. In fact,
many of the bleeds were acute and transient suggestive
of acute anal irritation or hemorrhoid exacerbation dueto bowel frequency [38]. Furthermore, the incidence of
telangiectasia in patients who completed post-SBRT rec-
tal endoscopy for the assessment of rectal bleeding or
cancer screening was 11% which is significantly lower
than the rates reported in prospective studies that looked
at endoscopic outcomes after conventionally fractionated
radiation therapy [17,46,47].
These findings are particularly significant given that
rectal bleeding is one of the principle dose-limiting
Figure 2 Average EPIC bowel summary scores at baseline and following SBRT for prostate cancer. Thresholds for clinically significant
changes in scores (½ standard deviation above and below the baseline) are marked with dashed lines. EPIC scores range from 0–100 with higher
values representing a more favorable health-related QOL.
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radiation at appropriately therapeutic levels. In the work
by Sanda et al, the proportion of patients reporting rec-
tal bleeding as a moderate-big problem on the EPIC 26
survey progressively increased over time (reaching 5%
at 12 and 24 months), ultimately manifesting as a late
complication post-treatment. However, we observed that
with SBRT rectal bleeding occurred at lower rates and
presented as a relatively earlier complication: the inci-
dence of patients reporting rectal bleeding as a moderate-
big problem in this study reached a peak at 9 months at
1.6%, and by 24 months the incidence dropped to null.
Additionally, in our series the rate of Grade 2-3 late rectal
bleeding was 1.5%. This compares favorably to the 5%-
15% seen with contemporary high-dose IMRT [24,48]. We
speculate that this reassuring profile with SBRT may be aTable 4 Overall bowel bother following SBRT for prostate cance
Start 1 3
No problem 76.0% 44.6% 6
Very small-small problem 19.9% 43.8% 2
Moderate-big problem 4.1% 11.5% 3
p value - <0.0001 0
N= 267 260 25result of the enhanced accuracy with fiducial tracking and
narrowed target volumes, thus enhancing our efforts to
spare normal tissue from inadvertent irradiation.
The pattern seen in bowel QOL after SBRT in our
study is similar to the pattern seen after conventionally
fractionated radiotherapy, proton therapy or brachyther-
apy. The bowel QOL score is at its lowest 1 or 2 months
after treatment, but improves slowly thereafter to near
baseline by 1-2 years after treatment [3-5]. In our series,
most moderate to big problems were seen at 1 month
post-SBRT with approximately 10% of patients reporting
moderate to big problems with bowel urgency and/or
frequency (Figure 4). This compares favorably with 15-
19% incidence of moderate to severe bowel urgency and
frequency seen two months after conventionally fraction-
ated external beam radiation therapy or brachytherapy [3].r (Patient-reported responses to Question 7 of the EPIC-26)
6 9 12 18 24
8.0% 69.1% 63.7% 63.5% 66.1% 70.4%
8.9% 26.9% 30.2% 29.5% 29.5% 26.3%
.1% 4.0% 6.0% 7.0% 4.5% 3.3%
.1044 0.0828 0.0051 0.0005 0.0172 0.3499
6 249 248 244 224 240
Figure 3 Overall bowel bother score (baseline and following SBRT; Question 7 of EPIC-26). Thresholds for clinically significant changes in
scores (½ standard deviation above and below the baseline) are marked with dashed lines. EPIC scores range from 0–100 with higher values
representing a more favorable health-related QOL.
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bother was transient and returned to near baseline by
3 months post-SBRT [3,5]. A second transient increase in
bowel bother occurred at 12 months with approximately
7% of patients reporting moderate to big problems. Unlike
the pattern seen with conventional modalities, post-SBRT
bowel bother returned to near baseline by two years [3,5].
The mean bowel summary score change from baseline to
24 months in this study was -1.6. This change compares
favorably to that seen at 24 months with conventionallyFigure 4 Radar plots showing the distribution of individual symptom
0–100 with higher values representing a more favorable health-related QO
with a given symptom.fractionated IMRT and proton therapy -7.4 and -3.7,
respectively [3-5,14].
The present study has several identifiable limitations.
The patient population was derived from a single high-
volume institution cohort that can limit the translation
of our work to the general population. Nevertheless, our
work utilized a fairly large patient population with excel-
lent follow-up rates, and was heterogeneous with respect
to ethnicity and risk stratification, and considered key
patient characteristics such as comorbidity, body massbother following SBRT for prostate cancer. EPIC scores range from
L. Points further out from the center indicate higher levels of bother
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It is conceivable, however, that institutions without the
same experience may have a learning curve before they
can achieve similar results. Also noteworthy is that our
analysis was conducted without a concurrent compara-
tor arm and thus must be carefully weighed against
previously published work. Reassuringly, given that the
observed toxicity rates in the acute phase are within
range of previous studies, the superior toxicity profile
at two years follow-up with SBRT compared to other
modalities offers intriguing insight to guide subsequent
trials for a more comprehensive assessments of SBRT-
related proctitis in the future.
Conclusions
In this single institution cohort, the rate and severity of
proctitis observed following SBRT is low. QOL tended
to improve with longer follow-up and was near baseline
at two years post-SBRT. Our results compare favorably
to those reported for patients treated with alternative ra-
diation modalities. Future prospective randomized stud-
ies are needed to confirm these observations.
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